US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

SIMPLIFY MANAGED FUTURES STRATEGY ETF

26.52

-0.9500-3.46%

Post-market: 26.46-0.0600-0.23%18:38 EDT

Volume:811.45K

Turnover:21.58M

Market Cap:- -

PE:- -

High:26.97

Open:26.97

Low:26.45

Close:27.47

Loading ...

Overview Company News Filings

Press Release: CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update

Why Prime Medicine Stock Was Climbing Higher This Week

Press Release: Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

ProQR Announces Year End 2024 Operating and Financial Results

Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Tired of subway delays? The MTA wants to fix that by strapping Google smartphones to New York trains

Press Release: Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results

Immunocore reports fourth quarter and full year 2024 financial results and provides a business update

Wolters Kluwer 2024 Full-Year Report

Voyager Provides Update on SOD1 ALS Gene Therapy Program

Excluding Ixom’s capital optimisation, KIT’s DPU rose 1% y-o-y in FY2024, but total DPU shows sharp decline

The Edge Singapore

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CTA/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CTA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTA\",,,,,undefined,":{"symbol":"CTA","market":"US","secType":"STK","nameCN":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","latestPrice":26.52,"timestamp":1754078400000,"preClose":27.47,"halted":0,"volume":811447,"hourTrading":{"tag":"盘后","latestPrice":26.46,"preClose":26.52,"latestTime":"18:38 EDT","volume":165,"amount":4367.66,"timestamp":1754087895204},"delay":0,"floatShares":40550001,"shares":0,"eps":0,"marketStatus":"Closed","change":-0.95,"latestTime":"08-01 16:00:00 EDT","open":26.97,"high":26.97,"low":26.45,"amount":21577708.125974,"amplitude":0.01893,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1754294400000},"marketStatusCode":5,"adr":0,"exchange":"AMEX","adjPreClose":27.47,"sharesOutstanding":40550001,"nav":27.42,"aum":1111996052.14,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":26.99,"preClose":27.47,"latestTime":"09:18 EDT","volume":117,"amount":3161.6899470000003,"timestamp":1754054322779},"postHourTrading":{"tag":"盘后","latestPrice":26.46,"preClose":26.52,"latestTime":"18:38 EDT","volume":165,"amount":4367.66,"timestamp":1754087895204},"volumeRatio":2.17607,"impliedVol":0.1468,"impliedVolPercentile":0.5847},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTA\",,,,,undefined,":{"symbol":"CTA","floatShares":40550001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.17607,"shares":0,"dividePrice":0,"high":26.97,"amplitude":0.01893,"preClose":27.47,"low":26.45,"week52Low":25.6601,"pbRate":"--","week52High":30.213,"institutionHeld":0,"latestPrice":26.52,"eps":0,"divideRate":0,"volume":811447,"delay":0,"ttmEps":0,"open":26.97,"prevYearClose":27.89,"prevWeekClose":28.08,"prevMonthClose":27.47,"prevQuarterClose":26.74,"fiveDayClose":28.08,"twentyDayClose":27.08,"sixtyDayClose":27.74},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CTA\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2522539191","title":"Press Release: CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2522539191","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522539191?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:05","pubTimestamp":1743105900,"startTime":"0","endTime":"0","summary":"-- Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders  ongoing, with dosing completed in two of four multiple ascending dose  cohorts; safety, pharmacokinetic, and pharmacodynamic data anticipated in Q4 2025. -- Nomination of development candidate CMP-SYNGAP-01 to address SYNGAP1-related disorders; GLP toxicology studies expected to be initiated in 2025. Mr. Mandel-Brehm continued, \"We are also pleased to announce the selection of a development candidate, CMP-SYNGAP-01, for our SYNGAP1-related disorders program based on compelling data across our preclinical studies, including recent non-human primate studies. The discovery and selection of a novel regRNA-targeting antisense oligonucleotide  that increases SYNGAP1 protein levels underscores the transformative potential of our platform to identify and advance this novel class of therapeutic candidates for SYNGAP1-related disorders, a group of neurodevelopmental conditions with no approved therapies that we believe impacts app","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4561","ASO","BK4200","BK4023","BK4588","BK4555","BK4139","BK4585","BK4604","LU1169589451.USD","TM","BK4020","CAMP","BK4099","CTA","PD","03160","LU1169590202.USD"],"gpt_icon":0},{"id":"2522580965","title":"Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2522580965","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522580965?lang=en_us&edition=fundamental","pubTime":"2025-03-26 19:01","pubTimestamp":1742986860,"startTime":"0","endTime":"0","summary":"- Announced first in vivo clinical validation for ARCUS gene editing across two distinct programs including wholly owned PBGENE-HBV and partnered program ECUR-506 -. - Commenced Phase 1 ELIMINATE-B clinical trial for PBGENE-HBV, the first gene editing technology studied for Hepatitis B, in fourth quarter of 2024 -. - Demonstrated PGENE-HBV was safe and well tolerated with substantial antiviral activity measured by reduction of Hepatitis B surface antigen after only one administration at lowest dose level; Subsequent doses of PBGENE-HBV to follow with data expected throughout 2025 -. \"In 2025, our steadfast focus remains on continued clinical execution as we work to deliver on the promise of our ARCUS gene editing technology through robust clinical data,\" continued Mr. Amoroso. \"The recent reported clinical experience for PBGENE-HBV focused on viral editing and elimination of replicating cccDNA and integrated HBV DNA in Hepatitis B, an extremely large patient population, adds to the com","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/precision-biosciences-reports-fourth-quarter-110100032.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CTA","BK4139","DTIL","GHS"],"gpt_icon":0},{"id":"2521418875","title":"Why Prime Medicine Stock Was Climbing Higher This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2521418875","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521418875?lang=en_us&edition=fundamental","pubTime":"2025-03-21 06:48","pubTimestamp":1742510880,"startTime":"0","endTime":"0","summary":"This is targeted at a genetic disorder that can affect the lungs and the liver.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/03/20/why-prime-medicine-stock-was-climbing-higher-this/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["CTA","BK4139","PRME"],"gpt_icon":0},{"id":"2520319811","title":"Press Release: Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2520319811","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520319811?lang=en_us&edition=fundamental","pubTime":"2025-03-20 04:01","pubTimestamp":1742414460,"startTime":"0","endTime":"0","summary":"-- Preclinical pipeline re-prioritization to focus on four potentially. transformative programs to advance toward clinic, led by CNTY-308 in. -- New concentrated clinical focus for CNTY-101 based on unique profile with. transformational potential in autoimmune disease; data anticipated in. -- Cash runway estimate extended into fourth quarter of 2026. PHILADELPHIA, March 19, 2025  -- Century Therapeutics, Inc. , an innovative biotechnology company developing induced pluripotent stem cell -derived cell therapies in autoimmune disease and cancer, today reported financial results and business highlights for the full year 2024.-- Phase 1 CALiPSO-1 trial site expansion in United States and Europe: The. first patient in our CALiPSO-1 Phase 1 trial in autoimmune diseases is. enrolled and scheduled for dosing in March 2025. Five sites in the U.S.are actively screening patients and Century has increased resourcing for. trial site activation and proficient recruitment. The company is also. expand","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","03160","BK4139","BK4539","BK4585","BK4505","BK4604","IPSC","LENZ","BK4588","BK4230","BK4099","TM","CNBKA","CAR","BK4022","CTA"],"gpt_icon":0},{"id":"2520623482","title":"Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2520623482","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520623482?lang=en_us&edition=fundamental","pubTime":"2025-03-18 19:00","pubTimestamp":1742295600,"startTime":"0","endTime":"0","summary":"-- Prime Editing has potential to be best-in-class approach for AATD -- -- Previously undisclosed program now emerging from within liver platform; leverages proprietary, universal liver LNP -- -- High","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/18/3044331/0/en/Prime-Medicine-Unveils-Program-for-the-Treatment-of-Alpha-1-Antitrypsin-Deficiency-AATD.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTA"],"gpt_icon":0},{"id":"2520688305","title":"Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2520688305","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520688305?lang=en_us&edition=fundamental","pubTime":"2025-03-18 04:05","pubTimestamp":1742241900,"startTime":"0","endTime":"0","summary":"Announced positive preliminary 12-week clinical results, building on already released 4-week results,of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplant","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/17/3044084/0/en/Sana-Biotechnology-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTA","SANA","BK4139"],"gpt_icon":0},{"id":"2519588080","title":"ProQR Announces Year End 2024 Operating and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2519588080","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519588080?lang=en_us&edition=fundamental","pubTime":"2025-03-13 19:00","pubTimestamp":1741863600,"startTime":"0","endTime":"0","summary":"Axiomer ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseasesCompany expects","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/13/3042018/33039/en/ProQR-Announces-Year-End-2024-Operating-and-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4523","BK4567","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","CTA","A","BK4121","LU2413666699.HKD","LU1721428933.USD","G","LU2092937221.SGD","LU0702159343.USD","IE00BN0W2W23.USD","LU1166156734.SGD","LU2413666426.HKD","LU0702159699.USD","BK4505","BK4106","BK4588","BK4226","LU2041044095.USD","LU0347712357.USD","BK4139","LU1165135440.EUR","LU1543694498.USD","BK4585","RNA"],"gpt_icon":0},{"id":"2518877129","title":"Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2518877129","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518877129?lang=en_us&edition=fundamental","pubTime":"2025-03-12 04:01","pubTimestamp":1741723260,"startTime":"0","endTime":"0","summary":"- Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing anticipated in 2026 - - Anti-tau antibody VY7523 was well","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/11/3040977/36461/en/Voyager-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-and-Operating-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSF","PET","BK4192","CTA"],"gpt_icon":0},{"id":"2518852512","title":"Tired of subway delays? The MTA wants to fix that by strapping Google smartphones to New York trains","url":"https://stock-news.laohu8.com/highlight/detail?id=2518852512","media":"CNN Business","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518852512?lang=en_us&edition=fundamental","pubTime":"2025-03-09 22:00","pubTimestamp":1741528852,"startTime":"0","endTime":"0","summary":"Rob Sarno has been with the New York City’s Metropolitan Transit Authority  for 14 years. As assistant chief track officer, he assists maintenance and emergency response — which also meant teaching artificial intelligence systems what a damaged rail sounds like last year.New York is just one major city to have implemented AI in the hopes of improving transit systems. In 2023, infrastructure consulting firm Aecom completed a pilot program for the New Jersey Transit system that used the technology to analyze customer flow and crowd management, and in 2024, the Chicago Transit Authority  uses AI to enhance security by detecting guns. Also in 2024, Beijing introduced a facial recognition system to be used in place of transit tickets and cards to reduce lines during rush hours.Google has partnered with other transportation agencies in the past. The tech giant has developed a chat box for the Chicago’s CTA, launched direct data integration for Amtrak departure and arrival times and has partn","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://edition.cnn.com/2025/03/09/tech/mta-google-pixel-smartphones-new-york-subways/index.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"cnn_highlight","symbols":["SGXZ31699556.SGD","LU1032955483.USD","LU2491050154.USD","LU0354030438.USD","LU2275660780.HKD","LU2552382058.USD","LU0289960550.SGD","LU2092627202.USD","LU2237443382.USD","LU1244550577.SGD","LU1548497426.USD","USJW.SI","LU1633808545.USD","LU0787776722.HKD","LU0528227936.USD","LU0788109477.HKD","LU0127658192.USD","BK4533","GOOG","LU1670628061.USD","LU2361044949.HKD","IE00BHPRN162.USD","LU0310800379.SGD","LU0157215616.USD","CTA","LU0444973449.USD","SG9999014914.USD","LU0426417589.USD","LU2063271972.USD","LU1803068979.SGD","LU0158827948.USD","LU1496350502.SGD","LU2097344431.USD","IE00BN29S564.USD","LU0878866978.SGD","LU1261432733.SGD","LU1551013342.USD","LU0053666078.USD","LU2087625088.SGD","BK4566","BK4548","LU0985489474.SGD","LU1267930490.SGD","LU0353189763.USD","MTA","LU0345769631.USD","GOOGL","LU1084165304.USD","LU2360032135.SGD","LU1923623000.USD"],"gpt_icon":1},{"id":"2516665944","title":"Press Release: Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2516665944","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516665944?lang=en_us&edition=fundamental","pubTime":"2025-03-04 05:05","pubTimestamp":1741035900,"startTime":"0","endTime":"0","summary":"Strong patient and physician demand for pivotal REMAIN-1 study highlights urgent need for post-GLP-1 withdrawal weight maintenance solutions; midpoint data analysis anticipated in Q2 2025 and full study enrollment expected in summer 2025. Company plans to submit first Clinical Trial Application  module for RJVA-001 in type 2 diabetes to regulators in H1 2025, and if CTA is authorized, expects to report preliminary data in 2026. BURLINGTON, Mass., March 03, 2025  -- Fractyl Health, Inc.  , a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes , is redefining the future of metabolic health by tackling one of obesity care's most urgent challenges -- sustaining weight loss after GLP-1 therapy. Today, the Company announced key anticipated milestones, growing patient and physician demand for its REMAIN-1 pivotal study, and fourth quarter and full year 2024 financial results, reinforcing its momentum for continued execution","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GUTS","BK4022","CTA","BK4232","BK4082","R"],"gpt_icon":0},{"id":"2516533666","title":"Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2516533666","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516533666?lang=en_us&edition=fundamental","pubTime":"2025-03-04 05:05","pubTimestamp":1741035900,"startTime":"0","endTime":"0","summary":"Discontinuation of BEACON-IPF following DSMB and outside expert panel recommendation SOUTH SAN FRANCISCO, Calif., March  03, 2025  (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clini","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/03/3036046/0/en/Pliant-Therapeutics-Provides-Corporate-Update-and-Reports-Fourth-Quarter-2024-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","FVC","CTA"],"gpt_icon":0},{"id":"2514983992","title":"Immunocore reports fourth quarter and full year 2024 financial results and provides a business update","url":"https://stock-news.laohu8.com/highlight/detail?id=2514983992","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514983992?lang=en_us&edition=fundamental","pubTime":"2025-02-26 20:00","pubTimestamp":1740571200,"startTime":"0","endTime":"0","summary":"KIMMTRAK  Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025. Executing on KIMMTRAK lifecycle management with two Phase 3 trials  in additional melanoma indications. Advancing PRAME portfolio – first patient randomized in Phase 3 PRISM-MEL-301; enrollment continues in Phase 1/2 trial of brenetafusp combinations in ovarian cancer and NSCLC; first patient dosed in Phase 1 trial of IMC-P115C . First patient dosed in Phase 1/2 trial of IMC-R117C  in colorectal and other gastrointestinal cancers. CTA/IND on track for IMC-S118AI  in 2H 2025 and for IMC-U120AI, our first non-HLA-restricted candidate initially for atopic dermatitis, in 2026. Cash, cash equivalents and marketable securities of $820.4 million as of December 31, 2024. “In 2024, we continued to grow KIMMTRAK sales, execute on our KIMMTRAK lifecycle management program, advance our deep clinical pipeline, and expand into autoimmune diseases, supported by a strong cash position and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immunocore-reports-fourth-quarter-full-120000489.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1093756325.SGD","BK4211","CRS","BK4548","BK4139","BK4533","CTA","IE00B66KJ199.SGD","LU1721428933.USD","IE00B19Z4B17.USD","BK4599","BK4147","BK4006","CM","BK4195","IE0031619046.USD","ORR","IE00BFXG0V08.USD","BK4585","LU0347712357.USD","IMCR","BK4007","ALT","BK4207","IE00B7SZL793.SGD","BK4588","LU1093756168.USD","BK4097","LU2413666426.HKD","BK4567","LU1878469433.USD","BK4121","LU2065731478.USD","ATOM","IE00BYQQ9H92.USD","OS","LU2413666699.HKD","BK4505","PROC","MTD","PFS"],"gpt_icon":0},{"id":"2514009958","title":"Wolters Kluwer 2024 Full-Year Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2514009958","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514009958?lang=en_us&edition=fundamental","pubTime":"2025-02-26 15:00","pubTimestamp":1740553200,"startTime":"0","endTime":"0","summary":"Alphen aan den Rijn, February 26, 2025 – Wolters Kluwer, a global leader in professional information solutions, software and services, today releases its full-year 2024 results.Revenues 5,916 million, up 6% in constant currencies and up 6% organically.Recurring revenues  up 7% organically; non-recurring trends varied.Adjusted operating profit 1,600 million, up 8% in constant currencies.Diluted adjusted EPS 4.97, up 9% overall and up 11% in constant currencies.Adjusted free cash flow 1,276 million, up 9% in constant currencies, ahead of expectation.Net-debt-to-EBITDA of 1.6x; return on invested capital  improved to 18.1%.Proposed 2024 total dividend 2.33 per share, an increase of 12%.Nancy McKinstry, CEO and Chair of the Executive Board, commented: “Wolters Kluwer delivered another year of 6% organic growth and a further increase in the adjusted operating profit margin. Recurring revenues, in particular cloud software subscriptions, continued to be the main driver of our growth. We main","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/wolters-kluwer-2024-full-report-070000393.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["A","ROIC","BK4212","LU0320765646.SGD","K","BK4106","BK4080","IE00BSNM7G36.USD","LU2456880835.USD","WTKWY","LU2092937221.SGD","LU0130517989.USD","G","LU1165135440.EUR","H","BK4567","F","D","LU0347712357.USD","BK4585","BK4574","LU1668664300.SGD","LU2236285917.USD","LU2417539215.USD","GHG","WOLTF","DRIP","IE00BZ18W340.USD","LU0098860793.USD","LU0052756011.USD","LU2360032135.SGD","BK4139","BK4231","BK4156","BK4207","BOLD","CTA","J","LU1166156734.SGD","IE00BN0W2T93.GBP","E","LU1721428933.USD","LU1543694498.USD","BK4555","LU0702159343.USD","LU0477156953.USD","BK4523","LU1201861249.SGD","LU2125154778.USD"],"gpt_icon":0},{"id":"2510005378","title":"Voyager Provides Update on SOD1 ALS Gene Therapy Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2510005378","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510005378?lang=en_us&edition=fundamental","pubTime":"2025-02-11 20:00","pubTimestamp":1739275200,"startTime":"0","endTime":"0","summary":"- Company to assess alternate payloads; no changes planned to novel capsid component -  - Resulting shift of timeline and costs extends cash runway into mid-2027 –   - All other programs remain on tra","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/11/3024034/36461/en/Voyager-Provides-Update-on-SOD1-ALS-Gene-Therapy-Program.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTA"],"gpt_icon":0},{"id":"2508455190","title":"Excluding Ixom’s capital optimisation, KIT’s DPU rose 1% y-o-y in FY2024, but total DPU shows sharp decline","url":"https://stock-news.laohu8.com/highlight/detail?id=2508455190","media":"The Edge Singapore ","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508455190?lang=en_us&edition=fundamental","pubTime":"2025-02-04 00:49","pubTimestamp":1738601347,"startTime":"0","endTime":"0","summary":"Keppel Infrastructure Trust announces sharp decline in total DPU, but 1% y-o-y growth in DPU excluding 2.33 cents from Ixom's capital optimisation ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theedgesingapore.com/capital/results/excluding-ixoms-capital-optimisation-kits-dpu-rose-1-y-o-y-fy2024-total-dpu-shows?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"edge_highlight","symbols":["A7RU.SI","SG9999005177.SGD","SG9999001127.SGD","NEA","LU0516423174.USD","SGXZ58947870.SGD","BK6102","LU1242518931.SGD","SG9999001135.SGD","SGXZ43160589.SGD","SG9999004360.SGD","SG9999014492.USD","LU0979878070.USD","LU1242518857.USD","BK6523","SG9999003461.SGD","SG9999013486.USD","BK6031","BN4.SI","LU0516422440.USD","SG9999001069.SGD","SG9999014484.SGD","SG9999016042.SGD","SG9999013478.USD","SG9999013460.SGD","SG9999003826.SGD","SGXZ27511609.SGD","SG9999014302.SGD","BK6501","SG9999002950.SGD","SG9999000343.SGD","SG9999006266.SGD","SG9999008742.SGD","SG9999000475.SGD","LU0516422366.SGD","SGXZ24219693.SGD","CTA","LU0516423091.SGD","BK6111","BK6505","LU0516422952.EUR"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":35,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CTA\",params:#limit:5,,,undefined,":[{"date":"2025-06-25","symbol":"CTA","amount":0.25,"announcedDate":"2025-06-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-25","defaultRemindTime":1750858200000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-30","payableDate":"2025-06-25","currency":"USD","dateTimestamp":1750824000000,"payDate":"2025-06-30"},{"date":"2025-03-26","symbol":"CTA","amount":0.12,"announcedDate":"2025-03-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-26","defaultRemindTime":1742995800000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-31","payableDate":"2025-03-26","currency":"USD","dateTimestamp":1742961600000,"payDate":"2025-03-31"},{"date":"2024-12-23","symbol":"CTA","amount":0.73816,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-31"},{"date":"2024-09-25","symbol":"CTA","amount":0.3,"announcedDate":"2024-09-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-09-25","defaultRemindTime":1727271000000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-09-30","payableDate":"2024-09-25","currency":"USD","dateTimestamp":1727236800000,"payDate":"2024-09-30"},{"date":"2024-06-25","symbol":"CTA","amount":0.15,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-28","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-06-28"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CTA\",market:\"US\",,,undefined,":[{"executeDate":"2022-08-26","recordDate":"2022-08-29","paymentDate":"2022-08-31","value":0.15,"currency":"USD"},{"executeDate":"2022-09-27","recordDate":"2022-09-28","paymentDate":"2022-09-30","value":0.15,"currency":"USD"},{"executeDate":"2022-10-26","recordDate":"2022-10-27","paymentDate":"2022-10-31","value":0.15,"currency":"USD"},{"executeDate":"2022-11-25","recordDate":"2022-11-28","paymentDate":"2022-11-30","value":0.15,"currency":"USD"},{"executeDate":"2022-12-27","recordDate":"2022-12-28","paymentDate":"2022-12-30","value":1.11096,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CTA\",market:\"US\",delay:false,,,undefined,":{}}}